 this is a fda news release on the approval of recarbrio a combination of imipenem cilastatin and relebactam to treat hospital acquired bacterial pneumonia and ventilator associated bacterial pneumonia habp vabp in patients 18 years of age and older recarbrio was previously fda approved to treat patients with complicated urinary tract infections and complicated intra abdominal infections who have limited or no alternative treatment options 